Our Management Team

The Trellis management team brings more than 100 years of expertise to the discovery and development of therapeutic antibodies, leveraging the company's proprietary platform for antibody discovery.

	Dr. Stefan Ryser, President and Chief Executive Officer sryser@trellisbio.com President and Chief Executive Officer Dr. Stefan Ryser has held senior positions in both the pharmaceutical and biotechnology industries, was a managing partner of Bear Stearns Health Innoventures and has served on numerous boards of directors. Dr. Stefan Ryser held various senior management positions of increasing responsibility at F. Hoffmann-La Roche, including Chief of Staff for the President of Global Research and Development. Dr. Ryser was from 1989 to 1997 at Roche in Nutley, NJ as well as in Basel, Switzerland. While at Roche he led initiatives to assess the impact of emerging technologies on pharmaceutical research and development, and assisted in the establishment and management of strategic research and development alliances. He was a member of the joint steering committee with Millennium Pharmaceuticals and a liaison for new research projects with Genentech. Stefan Ryser founded and served as managing partner of Bear Stearns Health Innoventures, a $212 million private equity fund established in 2000. He also founded and managed, beginning in 1998, International Biomedicine Management Partners, a biotechnology venture fund. Previously, Dr. Ryser has served on numerous boards of directors in both public and private biotechnology companies. Before joining Trellis Bioscience, Dr. Ryser was CEO at A-Cube, a biotech company focusing on identifying B-cell epitopes. Prior to A-Cube he was SVP for corporate strategy at Telik, a company founded by Larry Kauvar, and VP of Business Development at Aridis Pharmaceuticals. Dr. Ryser earned his undergraduate degree in molecular biology and biochemistry and Ph.D. in Immunology at the University of Basel, Switzerland.
	Lawrence Kauvar, PhD, Founder and Senior Vice President Founder and Senior Vice President Larry Kauvar has built a 20-year reputation as an inventor of innovative platform technologies. Dr. Kauvar is an entrepreneur and scientist who founded Trellis and was previously the founder and Chief Scientific Officer of Telik, a small molecule drug company focused on oncology. He holds 40 US patents for methods, tools and drug compounds and is one of the inventors of CellSpot™, Trellis' core technology. Dr. Kauvar holds a PhD from Yale in Molecular Biophysics and Biochemistry, did his postdoctoral studies at Caltech and holds an undergraduate degree from Harvard University.
	Stote Ellsworth, Chief Technology Officer CTO Stote Ellsworth has led the engineering of Trellis’ antibody platform, CellSpot™, now generating a pipeline of therapeutic antibodies. Mr. Ellsworth has spent his career bringing high technology systems solutions to the life science industry. He joined Trellis in 2003 to bring to reality the company's CellSpot™ platform now responsible for generating a pipeline of totally human therapeutic antibodies directly from human blood. The platform blends life science technology in cell and molecular biology with state-of-the-art microscopy, software, and nanotechnology. Prior to Trellis, Mr. Ellsworth was the VP R&D and Chief Operating Officer at First Medical, a point-of-care cardiac diagnostic company acquired by Sigma in 2000. This was preceded by a role as Vice President of Engineering at Becton Dickinson where he was responsible for developing through commercial release numerous flow cytometry products which now dominate that market. He holds a degree in Bioscience Technology from the University of California Santa Cruz, a BA from Dartmouth in Engineering and Mathematics, and an MS in Electrical Engineering from Stanford University.
	Jack M. Anthony Business Development Jack Anthony brings extensive business development and biotech transaction experience from roles with Symphogen, Saegis, Tularik, and FibroGen. Jack M. Anthony has been CEO/CBO of a number of San Francisco Bay Area biotechnology companies including Osprey USA, Pharmix, Saegis, Tularik, FibroGen, Inhale and AIS. Jack began his life sciences career at Baxter Healthcare Corporation and for seventeen years held various sales, marketing and general management positions in the U.S. and internationally. He departed Baxter as a Vice President of the Blood Therapy Group. Jack has a BS in Biology from Allegheny College and served as a Navy officer for five years. Jack also founded BioMentorz™ in 2006, a business development consultancy which specializes in the biotechnology sector.